Bimiralisib, un inibitore topico PI3K/mTOR, dimostra un tasso di clearance del 92% e un'ottima tollerabilità in uno studio proof-of-concept sulla cheratosi attinica oggi, 01:28 ansa.it 0 0
Sonoma Biotherapeutics Congratulates Fred Ramsdell, PhD, Co-Founder and Scientific Advisory Board Chair, on Receiving the 2025 Nobel Prize in Physiology or Medicine... ieri, 21:00 ansa.it 0 0
Sonoma Biotherapeutics Congratulates Fred Ramsdell, PhD, Co-Founder and Scientific Advisory Board Chair, on Receiving the 2025 Nobel Prize in Physiology or Medicine... ieri, 21:00 ansa.it 0 0
TCG Crossover (“TCGX”) annuncia il fondo TCGX Fund III da 1,3 miliardi di dollari, sottoscritto in eccesso ieri, 20:51 ansa.it 0 0
Nessun commento